Gilead shares rise on HIV combo data

Shares of Gilead Sciences moved up yesterday on the news that its new HIV combo drug dubbed Quad was just as effective as the popular Atripla in a mid-stage trial. Quad combines the approved Truvada therapy with two new agents: elvitegravir and cobicistat. Gilead's stock jumped 4 percent on the news. Report